NASH Drug Development: Experts Argue The Case For Noninvasive Tests As Surrogate Endpoints For Approval

 
• By Sue Sutter
  
Cairns
An FDA official cautioned against trying to build a surrogate on a surrogate. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards